SG11201908166UA - Usl-311 for use in the treatment of cancer - Google Patents
Usl-311 for use in the treatment of cancerInfo
- Publication number
- SG11201908166UA SG11201908166UA SG11201908166UA SG11201908166UA SG 11201908166U A SG11201908166U A SG 11201908166UA SG 11201908166U A SG11201908166U A SG 11201908166UA SG 11201908166U A SG11201908166U A SG 11201908166UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- treatment
- proximagen
- minerva
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1703907.4A GB201703907D0 (en) | 2017-03-10 | 2017-03-10 | Novel therapies for cancer |
| PCT/GB2018/050608 WO2018162924A1 (en) | 2017-03-10 | 2018-03-09 | Usl-311 for use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908166UA true SG11201908166UA (en) | 2019-10-30 |
Family
ID=58605592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908166U SG11201908166UA (en) | 2017-03-10 | 2018-03-09 | Usl-311 for use in the treatment of cancer |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200281937A1 (ru) |
| EP (1) | EP3592356A1 (ru) |
| JP (1) | JP2020514345A (ru) |
| KR (1) | KR20190128660A (ru) |
| CN (1) | CN110520130A (ru) |
| AU (1) | AU2018231664A1 (ru) |
| BR (1) | BR112019018482A2 (ru) |
| CA (1) | CA3055470A1 (ru) |
| EA (1) | EA201992130A1 (ru) |
| GB (1) | GB201703907D0 (ru) |
| IL (1) | IL269121A (ru) |
| MX (1) | MX2019010679A (ru) |
| SG (1) | SG11201908166UA (ru) |
| WO (1) | WO2018162924A1 (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201017345D0 (en) | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
| BR112017019437A2 (pt) | 2015-04-02 | 2018-05-02 | Proximagen Ltd | terapias para câncer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201017345D0 (en) * | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
| WO2015019284A2 (en) * | 2013-08-05 | 2015-02-12 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
| BR112017019437A2 (pt) * | 2015-04-02 | 2018-05-02 | Proximagen Ltd | terapias para câncer |
| GB201604213D0 (en) * | 2016-03-11 | 2016-04-27 | Proximagen Ltd | Drug combination and its use in therapy |
-
2017
- 2017-03-10 GB GBGB1703907.4A patent/GB201703907D0/en not_active Ceased
-
2018
- 2018-03-09 CA CA3055470A patent/CA3055470A1/en not_active Abandoned
- 2018-03-09 AU AU2018231664A patent/AU2018231664A1/en not_active Abandoned
- 2018-03-09 SG SG11201908166U patent/SG11201908166UA/en unknown
- 2018-03-09 KR KR1020197028679A patent/KR20190128660A/ko not_active Application Discontinuation
- 2018-03-09 MX MX2019010679A patent/MX2019010679A/es unknown
- 2018-03-09 BR BR112019018482A patent/BR112019018482A2/pt not_active Application Discontinuation
- 2018-03-09 JP JP2019549449A patent/JP2020514345A/ja active Pending
- 2018-03-09 EP EP18711658.7A patent/EP3592356A1/en not_active Withdrawn
- 2018-03-09 CN CN201880024349.5A patent/CN110520130A/zh active Pending
- 2018-03-09 WO PCT/GB2018/050608 patent/WO2018162924A1/en unknown
- 2018-03-09 EA EA201992130A patent/EA201992130A1/ru unknown
- 2018-03-09 US US16/492,305 patent/US20200281937A1/en not_active Abandoned
-
2019
- 2019-09-04 IL IL26912119A patent/IL269121A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20200281937A1 (en) | 2020-09-10 |
| MX2019010679A (es) | 2020-02-05 |
| WO2018162924A1 (en) | 2018-09-13 |
| EP3592356A1 (en) | 2020-01-15 |
| IL269121A (en) | 2019-11-28 |
| CN110520130A (zh) | 2019-11-29 |
| GB201703907D0 (en) | 2017-04-26 |
| AU2018231664A1 (en) | 2019-09-26 |
| CA3055470A1 (en) | 2018-09-13 |
| BR112019018482A2 (pt) | 2020-04-14 |
| JP2020514345A (ja) | 2020-05-21 |
| EA201992130A1 (ru) | 2020-02-04 |
| KR20190128660A (ko) | 2019-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201807549TA (en) | Combination of a cxcr4 antagonist and an immune checkpoint inhibitor | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201909168VA (en) | Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor | |
| SG11201811148SA (en) | Cell penetrating peptide (cpp)-mediated ev loading | |
| SG11201903938XA (en) | Acylated glp-1/glp-2 dual agonists | |
| SG11201806485RA (en) | Pyrrolobenzodiazepine conjugates | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201805072PA (en) | Nicotine powder delivery system | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201906041QA (en) | Pharmaceutical compositions for combination therapy | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201906987RA (en) | Combination of a ppar agonist with a fxr agonist | |
| SG11201909224QA (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201805755SA (en) | Methods of administering hepcidin | |
| SG11201902949PA (en) | Pharmaceutical compositions and methods of treating cardiovascular diseases | |
| SG11201900043TA (en) | Antibody formulations | |
| SG11201908228TA (en) | Chemical compounds | |
| SG11201907844TA (en) | Novel spiro and cyclic bis-benzylidine proteasome inhibitor for the treatment of cancer, diabetes and neurological disorders | |
| SG11201900214UA (en) | Iso-citrate dehydrogenase (idh) inhibitor |